EW vs SNN stock comparison
Edwards Lifesciences vs. Smith & Nephew · data as of November 13, 2026
Edwards Lifesciences (EW) has a market value of about $61.6B, Smith & Nephew (SNN) about $13.1B. Over their latest twelve months Edwards Lifesciences had revenue of $6.7B and Smith & Nephew $6.3B.
On our five checks Edwards Lifesciences scores higher: 2.8 out of 5 (average) against 2.6 (average).
By area, the stronger company is Smith & Nephew on value; Edwards Lifesciences on future growth; Edwards Lifesciences on track record; Edwards Lifesciences on financial health; Smith & Nephew on shareholder returns.
Smith & Nephew is cheaper on earnings (P/E 21.3 vs. 60.5), while Edwards Lifesciences grew revenue faster over five years (6.7% vs. 6.2% a year).
Edwards Lifesciences leads on 13 of the compared lines and Smith & Nephew on 12.
Side by side
| EW | SNN | |
|---|---|---|
| Size and price | ||
| Market cap | $61.6B | $13.1B |
| Share price | $107.15 | $31.28 |
| Score | ||
| Overall score (of 5) | 2.8 | 2.6 |
| Value | 0 | 3 |
| Future growth | 4 | 2 |
| Track record | 2 | 1 |
| Financial health | 5 | 3 |
| Shareholder returns | 3 | 4 |
| Valuation | ||
| P/E (TTM) | 60.5 | 21.3 |
| Forward P/E | 33.5 | 13.3 |
| Price / free cash flow | 43.3 | 15.3 |
| Price / sales | 9.2 | 2.1 |
| EV / EBITDA | 35.8 | 11.3 |
| PEG | 8.55 | 3.07 |
| DCF value vs. price | −64% | −17% |
| Business | ||
| Revenue | $6.7B | $6.3B |
| Net income | $1.0B | $635M |
| Free cash flow | $1.4B | $855M |
| Net margin | 15.3% | 10.1% |
| Gross margin (5-yr avg.) | 79.6% | 69.5% |
| ROIC (5-yr avg.) | 16.0% | 6.1% |
| Growth | ||
| Revenue growth (1 yr) | 11.6% | 6.1% |
| Revenue growth (5 yrs, per year) | 6.7% | 6.2% |
| EPS growth (5 yrs, per year) | 7.1% | 6.9% |
| Balance sheet and payouts | ||
| Net cash (cash minus debt) | $3.9B | -$2.6B |
| Dividend yield | None | 2.54% |
| Shareholder yield | 1.5% | 6.4% |
| Analysts | ||
| Upside to average target | +6% | +6% |
| Consensus rating | Buy | Hold |
Highlighted = the better figure on that line. Revenue, net income and free cash flow: EW TTM to September 30, 2026, SNN TTM to June 30, 2026. Not investment advice.
Frequently asked questions
Which is the better stock, Edwards Lifesciences or Smith & Nephew?
We do not give buy or sell advice. On our five checks (value, growth, track record, financial health and shareholder returns) Edwards Lifesciences scores 2.8 out of 5 and Smith & Nephew 2.6; the table shows where each one is stronger.
Is Edwards Lifesciences cheaper than Smith & Nephew?
On trailing earnings, Smith & Nephew trades at a P/E of 21.3 and Edwards Lifesciences at 60.5, so Smith & Nephew is cheaper by this measure. A lower P/E can also reflect slower expected growth.
Which grows faster, Edwards Lifesciences or Smith & Nephew?
Over five years Edwards Lifesciences grew revenue about 6.7% a year and Smith & Nephew about 6.2% a year.
Which pays a higher dividend?
Edwards Lifesciences yields nothing (no dividend) and Smith & Nephew 2.54%.
Full Edwards Lifesciences analysis → Full Smith & Nephew analysis →
More comparisons
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.